Status:
COMPLETED
Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Day Surgery
Patient Outcome Assessment
Eligibility:
FEMALE
19-75 years
Brief Summary
Remimazolam is a novel ultra-short acting benzodiazepine with rapid onset of effects, short maintenance and faster recovery time. Due to its recent development, few studies have investigated the effec...
Detailed Description
To date, there has not been a study investigating the impact of remimazolam on quality of recovery (QoR). This study evaluates the effect of remimazolam on QoR of participants undergoing general anest...
Eligibility Criteria
Inclusion
- Adult woman scheduled for ambulatory gynecological surgery under general anesthesia
- American Society of Anesthesiology grade 1 or 2
Exclusion
- Underlying diseases: liver, kidney, brain nervous system, glaucoma
- Patients with BMI greater than 30 and less than 18.5
- Patients diagnosed with sleep apnea
- Alcohol or drug dependent patients
- Patients with severe or acute respiratory failure
- Lactose intolerance
- Dextran 40 hypersensitivity
- Patients in shock or coma
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT05320016
Start Date
November 1 2021
End Date
December 31 2021
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyunggi-do, South Korea, 13620